Why Amgen Inc. (AMGN) stock moved
No significant move on Nov 19, 2026 (−1.1%, close-to-close). Latest notable session: Nov 18, 2026.
Why Amgen Inc. (AMGN) fell 3.1% on November 18, 2026
Amgen Inc. (AMGN) fell 3.1% on November 18, 2026, closing at $443.89 versus $457.93 the prior session (close-to-close, from daily closes). Amgen reaches proposed settlement in securities litigation filed in Southern District of New York. Source: Business Wire.
Amgen reaches proposed settlement in securities litigation filed in Southern District of New York.
What to watch next: Settlement resolves shareholder lawsuit, reducing legal uncertainty and potential financial liability for Amgen.
Earlier sessions that moved AMGN
- −3.8%After reporting Q3 FY2026 earnings on 2026-11-03 that beat consensus EPS by 11.40% ($6.45 reported vs. $5.79 estimate).
- +3.7%Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks.
- −0.9%Amgen Inc. (AMGN) reported EPS of $6.45 vs. consensus estimate of $5.79, beating by 11.4% on 2026-11-03.
- +3.3%Amgen's co-developed asthma drug Tezspire achieved 69% histologic remission in an eosinophilic esophagitis trial, with statistically significant symptom improvement sustained through week 52 versus placebo, per a press release dated 2026-10-20.
- +3.2%Driven by institutional buying activity, recent analyst price-target upgrades (UBS raised its target to $470), and optimism around its obesity pipeline candidate MariTide and growth drugs Repatha and Tezspire, according to the web catalyst.
- −3.4%We checked news, earnings, analyst updates, and filings — no company-specific catalyst was found.
- −10.1%After rival Novartis announced its Phase III cardiovascular trial for pelacarsen failed to meet primary endpoints, raising concerns about similar pipeline risks at AMGN.
Amgen Inc. (AMGN) shares rose 0.3% to $437.49 as of November 20, 2026, a slight gain from the prior close of $436.30. BestStocks flagged the session as a major change for AMGN. The move is tied to company news. Below, we break down what changed for AMGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Amgen reaches proposed settlement in securities litigation filed in Southern District of New York. Settlement resolves shareholder lawsuit, reducing legal uncertainty and potential financial liability for Amgen.
What it means for Amgen Inc. investors
For Amgen Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.3% session move; Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in AMGN's fundamentals. Wall Street's consensus price target sits at $426.29, implying -2.6% downside from $437.49. Over the past 90 days analysts logged 0 upgrades and 3 downgrades. BestStocks rates the overall signal quality weak (37/100). With earnings roughly 74 days out, the next report is the most likely near-term test of the move.
AMGN price reaction
AMGN last traded at $437.49, up $1.19 (+0.27%) from the previous close of $436.30. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.8% over the same stretch, leaving AMGN behind the group by 1.5 points.
Bullish and bearish analyst opinions on Amgen Inc. (AMGN)
The consensus analyst price target on Amgen Inc. (AMGN) is $426.29, 2.6% below the recent $437.49. Over the past 90 days analysts logged 0 upgrades, 29 maintains, and 3 downgrades. Here is how the bullish and bearish cases on AMGN line up.
The bullish case
- The Street's most bullish target is $531.00 (+21.4%).
- Positive 0.3% session move.
- Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $426.29 sits 2.6% below the recent $437.49, so the average target sees limited room to run.
- The most bearish analyst target is $230.00 (-47.4%).
- 3 analyst downgrades in the past 90 days, most recently Freedom Broker to Hold (2026-11-06).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for AMGN
Frequently asked questions about AMGN
Why did Amgen Inc. (AMGN) stock move?
Amgen Inc. (AMGN) fell 3.1% on November 18, 2026, closing at $443.89 versus $457.93 the prior session (close-to-close, from daily closes). Amgen reaches proposed settlement in securities litigation filed in Southern District of New York. Source: Business Wire.
How much did AMGN stock rise?
AMGN gained 0.27% ($1.19) versus the prior close of $436.30, last trading at $437.49 on 0.6× average volume.
When is Amgen Inc.'s next earnings date?
AMGN's next earnings report is estimated for 2027-02-02 — about 74 days away.
What is the analyst price target for AMGN?
The consensus analyst price target for AMGN is $426.29, about 2.6% below the current $437.49. Over the past 90 days, analysts recorded 0 upgrades, 29 maintains, and 3 downgrades.
Is the AMGN move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +1.8% against AMGN's +0.3%. AMGN ranks top 5 of 7 peers.
How BestStocks tracks AMGN
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for AMGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

